Atlas Trials

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Clinical trial NCT03533257 · COMPLETED

Trial details

NCT number
NCT03533257
Sponsor
Amylyx Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Alzheimer Disease
Start date
2018-09-14
Primary completion
2020-10-22
Enrollment
95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.